VTRS

AI Research

UBS raises target to $20; FDA accepts phentolamine NDA with October 2026 PDUFA date

UBS raised its Viatris price target to $20 from $18 on February 27, 2026, following an earlier upgrade from Neutral to Buy with the target raised from $11. The FDA accepted the supplemental NDA for MR-141 (phentolamine ophthalmic solution 0.75%) for presbyopia, with a PDUFA goal date of October 17, 2026. The company reported Q4 2025 total revenues of $3.7B and FY2025 revenues of $14.3B, returned over $1B to shareholders, and expects up to $650M in net cost savings from its strategic review.